Show simple item record

dc.contributor.authorFrizziero, Melissa
dc.contributor.authorLamarca, Angela
dc.contributor.authorKordatou, Zoe
dc.contributor.authorBarriuso, Jorge
dc.contributor.authorNuttall, Christina
dc.contributor.authorMcNamara, Mairéad G
dc.contributor.authorHubner, Richard A
dc.contributor.authorMansoor, Was
dc.contributor.authorManoharan, Prakash
dc.contributor.authorValle, Juan W
dc.date.accessioned2018-05-15T20:18:45Z
dc.date.available2018-05-15T20:18:45Z
dc.date.issued2018
dc.identifier.citationCarboplatin-etoposide chemotherapy (CB-ET) for patients diagnosed with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC): findings from a European Neuroendocrine Tumor Society Centre of Excellence. 2018, 106: 77-77 Neuroendocrinologyen
dc.identifier.urihttp://hdl.handle.net/10541/621019
dc.language.isoenen
dc.titleCarboplatin-etoposide chemotherapy (CB-ET) for patients diagnosed with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC): findings from a European Neuroendocrine Tumor Society Centre of Excellence.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalNeuroendocrinologyen


This item appears in the following Collection(s)

Show simple item record